Stock Screener App

Gratuito -

Installare

Drug Manufacturers - Major

67.57

0.40% 0.27

Astrazeneca PLC (AZN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché AZN Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Astrazeneca PLC Borsa (AZN) Ultime notizie

AstraZeneca's bladder cancer treatment shows positive results in trial - Seeking Alpha

AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens By Stocktwits - Investing.com India

AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Cancer Treatment | AZN Stock News - GuruFocus

AstraZeneca Pharma India gets CDSCO approval for Enhertu for new breast cancer indication - Medical Dialogues

AstraZeneca’s Imfinzi delays bladder cancer return in high-risk patients - Proactive Investors

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC - DirectorsTalk Interviews

Astrazeneca Says Imfinzi Improved DFS In Early Bladder Cancer - marketscreener.com

AstraZeneca (AZN) Sees Increased Bullish Option Activity | AZN Stock News - GuruFocus

US court shuts down AstraZeneca's challenge to Medicare drug price plan - Reuters

Investors who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class ActionAZN - ACCESS Newswire

High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

June 27th Options Now Available For AstraZeneca - Nasdaq

AstraZeneca Loses Bid to Revive Drug Price Suit on Appeal (1) - Bloomberg Law News

Britain set to strike first deal to cut Trump tariffs - marketscreener.com

Does the GSK or AstraZeneca share price currently offer the best value? - MSN

AstraZeneca (AZN) Achieves Key Milestone with Enhertu in Breast Cancer Trial - GuruFocus

AstraZeneca marks Enhertu trial win in breast cancer (AZN) - Seeking Alpha

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment - Yahoo Finance

AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study - marketscreener.com

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment - insights.citeline.com

ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Followed By THP Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In High-Risk HER2-Positive Early-Stage Breast Cancer In DESTINY- - marketscreener.com

AstraZeneca (AZN) Sees Positive Results in DESTINY-Breast11 Trial | AZN Stock News - GuruFocus

AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief - Proactive Investors

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga

Multiple System Atrophy (MSA) Market Research 2025-2035 - GlobeNewswire Inc.

AstraZeneca and GSK Share Price Slide as Markets React to Vinay Prasad’s FDA Appointment - paginasiete.bo

AstraZeneca plc (LON: AZN) Shares Fall 2.2% in Early Morning Trading - paginasiete.bo

REGAstraZeneca PLCEnhertu improved pCR in early-stage breast cancer - TradingView

AstraZeneca (AZN): Impact of FDA's New Inspection Strategy on Fo - GuruFocus

AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing - Yahoo Finance

AstraZeneca unveils $300M Rockville investment, a boost for MoCo amid federal cuts - The Business Journals

Berenberg: AstraZeneca, Eli Lilly Among Pharmaceutical Companies Set to Gain from US 'Pill Penalty' Update - marketscreener.com

AstraZeneca's (AZN) Calquence Gains EU Approval for Mantle Cell Lymphoma Treatment | AZN Stock News - GuruFocus

AstraZeneca's Calquence gets Europe approval for MCL - Sharecast.com

AstraZeneca Plc Calquence combo approved in EU for first-line MCL - DirectorsTalk Interviews

AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma - marketscreener.com

AstraZeneca: EU Approves Calquence Combination For 1st-line Mantle Cell Lymphoma - Nasdaq

AstraZeneca Says Calquence Combination Approved In EU For 1L MCL - marketscreener.com

AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye - Yahoo Finance

Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN - GuruFocus

Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN) | AZN Stock News - GuruFocus

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma - BioPharma Dive

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma - Yahoo Finance

AstraZeneca reports success in phase III asthma trials By Investing.com - Investing.com India

AstraZeneca reports success in phase III asthma trials - Investing.com

AstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trials - Reuters

AstraZeneca (AZN) Achieves Major Milestones in Asthma Treatment Trials - GuruFocus

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials - insights.citeline.com

AstraZeneca's (AZN) Breztri Aerosphere Achieves Key Milestones i - GuruFocus

AstraZeneca posts phase 3 win for asthma drug (AZN:NASDAQ) - Seeking Alpha

AstraZeneca’s asthma therapy shows promise in trials By Investing.com - Investing.com UK

AstraZeneca (AZN) Triple Therapy Shows Promise in Asthma Trials - GuruFocus

AstraZeneca (AZN) Triple Therapy Shows Promise in Asthma Trials | AZN Stock News - GuruFocus

AstraZeneca’s share price is down 20% from September, so is it time for me to buy? - MSN

AstraZeneca's Asthma Drug Improves Lung Function in Late-stage Studies - marketscreener.com

AstraZeneca Plc Breztri succeeds in Phase III asthma trials - DirectorsTalk Interviews

AstraZeneca's Breztri meets main goals of late-stage asthma trials - marketscreener.com

Astrazeneca Says Breztri Met Primary Endpoints In Ph3 Asthma Trials - marketscreener.com

AstraZeneca and AI startup join forces in the fight against lung cancer - Mugglehead Magazine

AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Call Transcript - MSN

AstraZeneca Director Buys ADSs Worth Over $100,000 - Investing.com

AstraZeneca reports total voting rights - Investing.com

AstraZeneca quietly exits neuroscience - BioPharma Dive

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters